A Phase Ib/II Trial of Trastuzumab-DM1 with Pertuzumab for Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer: Interim Efficacy and Safety Results

被引：1
|
作者：
Dieras, V.
Harbeck, N.
Albain, K.
Burris, H.
Awada, A.
Crivellari, D.
Andre, F.
Choi, Y. J.
Huang, J.
Miller, K. D.
机构：
[1] Inst Curie, Paris, France
[2] Univ Cologne, Cologne, Germany
[3] Loyola Univ, Maywood, IL 60153 USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Inst Jules Bordet, B-1000 Brussels, Belgium
[6] Ctr Riferimento Oncol, Aviano, Italy
[7] Inst Gustave Roussy, Villejuif, France
[8] Genentech Inc, San Francisco, CA 94080 USA
[9] IU Simon Canc Ctr, Indianapolis, IN USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P3-14-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-14-01
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T).
    Miller, K.
    Gianni, L.
    Andre, F.
    Dieras, V.
    Mahtani, R. L.
    Harbeck, N.
    Huang, J. E.
    Shih, T.
    Choi, Y.
    Burris, H. A., III
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
    Martin, M.
    Fumoleau, P.
    Dewar, J. A.
    Albanell, J.
    Limentani, S. A.
    Campone, M.
    Chang, J. C.
    Patre, M.
    Strasak, A.
    de Haas, S. L.
    Xu, J.
    Garcia-Saenz, J. A.
    ANNALS OF ONCOLOGY, 2016, 27 (07) : 1249 - 1256
  • [3] Interim safety of pertuzumab in combination with trastuzumab and vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
    Perez, E.
    Lopez-Vega, J. M.
    Petit, T.
    Zamagni, C.
    Freudensprung, U.
    Bastiere-Truchot, L.
    Walker, R.
    Andersson, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S178 - S179
  • [4] A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer
    Walshe, Janice M.
    Denduluri, Neelima
    Berman, Arlene W.
    Rosing, Douglas R.
    Swain, Sandra M.
    CLINICAL BREAST CANCER, 2006, 6 (06) : 535 - 539
  • [5] Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis
    Zhang, Jing
    Li, Jinying
    Zhu, Chenjing
    Song, Yanlin
    Xia, Fan
    Ma, Xuelei
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 3235 - 3244
  • [6] Interim Results from a Phase 1b/2a Study of Trastuzumab Emtansine and Docetaxel, With and Without Pertuzumab, in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer
    Martin, M.
    Garcia-Saenz, J. A.
    Dewar, J. A.
    Albanell, J.
    Limentani, S. A.
    Strasak, A.
    Patre, M.
    Branle, F.
    Fumoleau, P.
    CANCER RESEARCH, 2012, 72
  • [7] Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study
    Emi Noguchi
    Kenji Tamura
    Masaya Hattori
    Jun Horiguchi
    Nobuaki Sato
    Kazumitsu Kanatani
    Kiyoshi Matsunaga
    Hiroji Iwata
    Yasuhiro Fujiwara
    Breast Cancer, 2019, 26 : 39 - 46
  • [8] Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study
    Noguchi, Emi
    Tamura, Kenji
    Hattori, Masaya
    Horiguchi, Jun
    Sato, Nobuaki
    Kanatani, Kazumitsu
    Matsunaga, Kiyoshi
    Iwata, Hiroji
    Fujiwara, Yasuhiro
    BREAST CANCER, 2019, 26 (01) : 39 - 46
  • [9] Phase II open clinical trial to evaluate efficacy and safety of neoadjuvant trastuzumab in HER2-positive locally advanced breast cancer (LABC)
    Arce-Salinas, C. H.
    Lara, F. U.
    Leon, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results
    Perez, Edith A.
    Manuel Lopez-Vega, Jose
    Petit, Thierry
    Zamagni, Claudio
    Easton, Valerie
    Kamber, Julia
    Restuccia, Eleonora
    Andersson, Michael
    BREAST CANCER RESEARCH, 2016, 18
12345